PARPi such as olaparib and talazoparib have been proved to be beneficial for breast cancer carry BRCA1 or BRCA2 mutation in neoadjuvant, adjuvant as well as salvage therapy in later stage (23–26). Here, BRCA2 is linked to breast carcinoma.